Effects of methotrexate on vascular endothelial growth factor, angiopoietin 1, and angiopoietin 2 in nasal polyps

American Journal of Rhinology and Allergy

Volumn 25, Issue 4, 2011, Pages

  Park, Seong Kook ^a   Kim, Hyeong In ^a   Yang, Young Il ^a   Hur, Dae Young ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; EOSIN; HEMATOXYLIN; METHOTREXATE; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; EPITHELIUM; FIBROBLAST; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY CELL; MICROVASCULATURE; NICK END LABELING; NOSE POLYP; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE CULTURE;

ANGIOPOIETIN-1; CELLS, CULTURED; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHILS; GENE EXPRESSION REGULATION; HUMANS; METHOTREXATE; NASAL MUCOSA; NASAL POLYPS; ORGAN CULTURE TECHNIQUES; RHINITIS; SINUSITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VESICULAR TRANSPORT PROTEINS;

EID: 79960466220     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2011.25.3618     Document Type: Article

References (23)

1. Jahnesn FL, haraldsen G, Aanesen JP, et al. Eosinophil infiltration is related to increased expression of vascular cell adhesion molecule-1 in nasal polyps. Am J Respir Cell Mol Biol 12:624-632, 1995.
2. Jackson JR, Seed MP, Kircher CH, et al. The codependence of angiogenesis and chronic inflammation. FASEB J 11:457-465, 1997. (Pubitemid 27259987)
3. Carmeliet P. Manipulating angiogenesis in medicine. J Intern Med 255:538-561, 2004. (Pubitemid 38534868)
4. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470-1478, 1989. (Pubitemid 19272234)
5. Matsune S, Ohori J, Sun D, et al. Vascular endothelial growth factor produced in nasal glands of perennial allergic rhinitis. Am J Rhinol 22:365-370, 2008.
6. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997. (Pubitemid 27450643)
7. Iwama A, Hamaguchi I, Hashiyama M, et al. Molecular cloning and characterization of mouse TIE and TEK receptor tyrosine kinase genes and their expression in hematopoietic stem cells. Biochem Biophys Res Commun 195:301-309, 1993. (Pubitemid 23266532)
8. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 49:659-670, 2001. (Pubitemid 32146429)
9. Pujols L, Alobid I, Benitez P, et al. Regulation of glucocorticoid receptor in nasal polyps by systemic and intranasal glucocorticoids. Allergy 63:1377-1386, 2008.
10. Domingo CJ, Moreno A, Amengual MJ, et al. Twelve years' experience with methotrexate for GINA treatment step 5 asthma patients. Curr Med Res Opin 25:367-374, 2009.
11. Coste A, Brugel L, Maitre B, et al. Inflammatory cells as well as epithelial cells in nasal polyps express vascular endothelial growth factor. Eur Respir J 15:367-372, 2000. (Pubitemid 30085967)
12. Park SK, Kim HI, and Yang YI. Roles of vascular endothelial growth factor, angiopoietin 1, and angiopoietin 2 in nasal polyp. Laryngoscope 119:409-413, 2009.
13. Erbek SS, Erinanc H, Erbek S, et al. Expression of a disintegrin and metalloproteinase 33 protein in nasal polyposis: An immunohistochemical study. Am J Rhinol Allergy 24:79-82, 2010.
14. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: Developing guidance for clinical trials. Otolaryngol Head Neck Surg 135(suppl):S31-S80, 2006. (Pubitemid 44647480)
15. McDonald DM. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 164:S39-S45, 2001.
16. Lee OH, Xu J, Fueyo J, et al. Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1α levels in gliomas. Oncogene 27:1310-1314, 2007.
17. Kuijpers AL, and van de kerkhof PC. Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. Am J Clin Dermatol 1:27-39, 2000.
18. Crostein BN. Low-dose methotrxate: A mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57:163-172, 2005.
19. Comet R, Domingo C, Larrosa M, et al. Benefits of low weekly doses of methotrexate in steroid-dependent asthmatic patients. A double blind, randomized, placebo-controlled study. Respir Med 100:411-419, 2006.
20. Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexateL apoptosis and clonal delection of activated peripheral T cells. J Clin Invest 102:322-328, 1998. (Pubitemid 28335191)
21. Morabito L, Montessinos MC, Schreibman DM, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-medicated conversion of adenine nucleotides. J Clin Invest 101:295-300, 1998. (Pubitemid 28067325)
22. Nagashima M, Yoshino S, Aono H, et al. Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells. Clin Exp Immunol 116:360-365, 1999. (Pubitemid 29219737)
23. Buyukozturk S, Gelincik A, Aslan I, et al. Methotrexate: Can it be a choice for nasal polyposis in aspirin exacerbated respiratory disease? J Asthma 46:1037-1041, 2009.